Recommendation of the Scientific Committee on Occupational Exposure Limits for Lead and its Inorganic Compounds

Biological limit value, lead in blood (PbB): 30 µg/100 ml

Atmospheric limit values: inorganic lead (lead fumes and dusts of < 10 µm)
8 hour TWA: 100 µg/m³
STEL (15 mins): -
Additional classification: -

Substance:

<table>
<thead>
<tr>
<th>Substance</th>
<th>Lead</th>
<th>Pb</th>
</tr>
</thead>
<tbody>
<tr>
<td>EINECS N°</td>
<td>231-100 4</td>
<td></td>
</tr>
<tr>
<td>EEC N°</td>
<td>Classification: R61, R62 R20/22, R33</td>
<td></td>
</tr>
<tr>
<td>CAS N°</td>
<td>7439-92-1</td>
<td></td>
</tr>
<tr>
<td>MWt</td>
<td>207.19</td>
<td></td>
</tr>
<tr>
<td>Conversion factor (20°C, 101 kPa)</td>
<td>8.6 mg/m³ = 1 ppm</td>
<td></td>
</tr>
</tbody>
</table>

Occurrence/use:

Metallic lead is a lustrous blue-grey metal which rapidly becomes dull in air, and is soft, malleable and ductile. It has a MPt of 327.4 °C and a BPt of 1740 °C. A variety of forms of lead are used industrially, the most common being lead oxide (PbO) and red lead oxide (lead tetraoxide; Pb₃O₄).

Lead is a rare metal in the earth’s crust and its deposits are scattered throughout the world. The most common ore is galena (lead sulphide - 87% Pb). Lead is obtained from the ore by smelting to produce lead oxide, which is reduced to lead bullion then refined to remove other metallic impurities. Recycled or secondary lead is also an important source and is produced in a similar manner to primary lead refining. As a result of
industrial activity, lead is now a ubiquitous multimedia pollutant. The use of lead in petrol during the past 40-50 years was the most important anthropogenic source of lead for the general population from inhalation (directly proportional to Pb percentage and to petrol consumption) and from fallout and contamination of soil, plants and water (Arnetz and Nicolich, 1990). During the past 10-15 years, directives have been adopted for reducing and replacing lead in petrol in the industrialised countries. As a result, lead in air and in blood dropped: a 3-4 fold reduction of lead in petrol led to a decrease in PbA from 1-2 µg/m³ to 0.5-1 µg/m³ and blood lead in the general population moved from 15-20 µg/dl to 5-10 µg/dl or less (Ducoffre et al., 1990). Currently, the general population is exposed to the following sources of the metal: foodstuffs, including alcohol, particularly wine; water; air, resulting from lead still used in petrol and from pollutant industries of activities; "adventitious sources", such as house or street dusts, paint flakes, soil, which are of great importance for particular groups of the population such as children.

The production rate in the EU is in excess of 10⁹ tonnes per annum. Occupational exposure occurs in a wide variety of industries, including procedures involved in production of lead metal and its compounds, manufacture of batteries, ceramics, jewellery, glass and pigments, and in the pottery, shipbuilding, construction, demolition and scrap industries. Exposure occurs by inhalation and ingestion, the predominant route varying with the industry and process. Lead can be present in the atmosphere as fume, which is generated at temperatures greater than 500 °C, and as dust. From the main investigations carried out between 1980 and 1995, the mean PbB in occupational exposure groups ranges from 20 to 40 µg/dl. In the two most important activities using Pb (accumulators, ceramics) median PbB ranges between 25 and 30 µg/dl, while the percentage of workers with PbB exceeding 40 µg/dl lies between 5% and 10%. The risk is concentrated in particular activities (lead scrap foundries, radiator repair, bronze foundries) and in small factories in which preventive measures are inefficient or absent.

In monitoring occupational exposure to lead, two indicators are generally used: Pb in air (PbA) and Pb in blood (PbB). It has been claimed that to determine compliance with limits, PbA is preferable to PbB because of the analytical difficulties in measuring PbB and the different medical and legal implications of the two tests. However, because the adverse health effects of lead correlate better or only with PbB, it was necessary to correlate PbA with PbB, to be able to demonstrate that compliance with a given environmental limit guarantees compliance with the given biological levels of the metal. This approach was suggested until the end of the 1970’s and it was argued that standards should be based only or mainly on PbB, and in the last 10 years, diffusion and improvement of analytical methods and instruments have been clearly demonstrated (Alessio and Foa, 1993).

In determining the PbA/PbB ratio in the working environment, the multicompartmental model developed by Bernard (1977) has been widely used, in particular by the OSHA in the so-called "Assumption C", which considers the percentage of particles with diameter less than 1µm, the different percentage for absorption by respiratory and digestive apparatus, the job tenure and the initial level of PbB absorption. The most widely questioned aspects of this assumption are: the definition of the granulometry of the dusts, not confirmed in many working conditions, the predicted percentage of
absorption, high only for particles less than 1µm and the failure to assess other variables, such as solubility of Pb compounds in biological media.

The contemporary use of indicators without solving the different aspects of their relationship may generate many of the problems encountered in monitoring Pb exposure. Another order of problems may arise from the use of some effect indicators, currently proposed for in controlling exposed workers. This use follows their suggested and partially demonstrated relationship with PbB and PbA. Urinary δ-aminolaevulinic acid (UALA) for example is well correlated only with PbB levels higher than 60 µg/dl, but there are some problems in determining the correspondence between its limit value and the PbB limit. Applying the most accepted dose effect model to the UALA limit value of 20 mg/g creatinine (from Directive 82/605/EEC), would indicate a PbB level higher than the corresponding PbB limit values of 80 µg/dl. More realistic studies suggest UALA values of 5-10 mg/l correspond to the current limit values of PbB (60-70 µg/dl) as determined by different national regulations within the EU. A good correlation between zinc protoporphyrin (ZPP) and PbB has also been suggested, indicating that ZPP could be a useful parameter for monitoring individual exposure. Exclusive use of ZPP for controlling worker exposure has been criticised mainly for its low sensitivity and for the high percentage of false negatives in predicting PbB of less than 40 µg/dl. For monitoring exposure of this entity, the ZPP is not accurate, and it is preferable to measure PbB directly (Apostoli and Maranelli, 1996; Verschoor et al., 1987; Letourneau et al., 1988).

**Health Significance**

The possible PbB levels and related effects in exposed workers are listed in the attached Figure 1.

**General Remarks and Toxicokinetics**

There is a vast data-base on human health effects of lead, none of which specifically relates to effects of single exposures, and the majority use blood lead (PbB) as a measure of exposure or body burden. The relationship between PbB and exposure in the workplace is not consistent, and in addition to recent occupational exposure, PbB is determined by other sources of uptake and by endogenous release from bone. Lead and its inorganic compounds have been shown to have diverse biological effects in humans, involving the cardiovascular, nervous, gastrointestinal, haemopoietic and reproductive systems, and only those considered to be most pertinent to occupational exposure are considered here.

The toxicity of lead compounds is thought to be due to the lead cation, and most studies relate effects to the amount of absorbed lead, irrespective of whether the source is metallic lead or an inorganic compound. There are few data on acute toxicity in animals, and no data relating to skin, eye or respiratory tract irritation and sensitisation potential. However, prediction and human experience suggests that these endpoints are not of significant concern in relation to elemental and inorganic lead. The effects of repeated exposure have been extensively investigated in animal models, mainly with the oral
route of administration. Effects on the haemopoietic, renal, nervous and reproductive systems have been reported.

When inhaled, in most inorganic forms lead deposited in the alveolar regions appears to be almost completely absorbed (Chamberlain, 1985; Morrow et al., 1980) although it is possible that lead compounds of low solubility, such as lead sulphide, may accumulate to some extent in the lung (Gerhardtsson et al., 1988). Gastrointestinal absorption of lead is relatively poor in adults (James et al., 1985), but little is known about comparative rates of gastrointestinal absorption of different forms of lead. Dermal absorption is likely to be minimal (Florence et al., 1988). Once absorbed, the toxicokinetic profiles of metallic lead and its inorganic compounds are assumed to be similar. Approximately 94% of the total body burden of adults is located in bone (Barry, 1975), from which it may be mobilised to form a major source of blood lead in persons with previous exposures (Schütz et al., 1987). Lead may also cross the placenta (Ernhart, 1992), and be transmitted to breast milk (Rabinowitz et al., 1985). In humans elimination half-lives for lead in blood and soft tissues have been estimated to be about 30 to 40 days, whereas for bone the half-life is likely to be in excess of 20 years (Rabinowitz et al., 1976). Urine is the primary route of excretion. Recently, the theory has been put forward that genetically determined polymorphisms of enzymes inhibited by lead influence the overall extent of lead binding, and might thereby modify lead toxicity Silbergeld et al., 2000). Specifically, ALAD occurs in two common alleles, ALAD-1 and ALAD-2 (Petrucci et al., 1982). Persons homozygous or heterozygous for ALAD-2 show significantly higher mean lead blood levels at equivalent exposure levels than persons homozygous for ALAD-1 (Petrucci er al., 1982; Wetmur et al., 1991). As an explanation, it has been postulated that ALAD-2 in circulating red blood cells binds lead more avidly than ALAD-1, thus increasing the blood lead level, but at the same time reducing the amount of lead delivered to soft tissues (Smith et al., 1995).

Genotoxicity and Carcinogenicity

Lead has been tested for genotoxic potential in a range of mutagenicity assays, with equivocal results, which may be related to poor compatibility of the materials with the test systems (Winder and Bonin, 1993). In total, lead is mostly negative in genotoxicity assays, but there is evidence that exposures of cells in culture can induce chromosomal aberrations (Silbergeld et al., 2000). Also, cytogenetic effects (chromosome aberrations and sister chromatid exchanges) have been reported in some, but not all, studies of lead-exposed workers (IARC, 1987). The significance of these effects is not clear. The idea has been put forward that the carcinogenic activity of lead is based on an indirect role in carcinogenises, e.g., in inhibiting DNA repair, rather than in causing alterations in DNA directly (Silbergeld et al., 2000).

Some lead compounds have been shown to be carcinogenic in animals, producing kidney tumours in particular, including carcinomas, at exposure levels that cause chronic renal tissue damage. Tumours at other sites have also been reported. IARC (1987) concluded that there was "sufficient evidence in experimental animals for the carcinogenicity of lead". The mechanism(s) of carcinogenicity is not clearly established; cytotoxicity may well be involved, although the genotoxic potential of lead remains uncertain (v.s.).
The potential carcinogenicity of lead has been investigated in a number of epidemiological studies in lead-exposed workers (IARC, 1987). In 1995, Fu and Boffetta reviewed the epidemiological evidence on the carcinogenicity of inorganic lead, and combined the published data for meta-analysis. Results from all industries entailing exposure to lead at varying intensities, indicated a slight to moderate, but statistically significant excess of deaths from stomach cancer (RR 1.33, 95%CI 1.18-1.49), lung cancer (RR 1.29, 95%CI 1.10-1.50) and bladder cancer (RR 1.41, 95%CI 1.16-1.71), and a non-significant excess from kidney cancer (RR 1.19, 95%CI 0.96-1.48). The meta-analysis for the studies in industries with heavy exposure to lead (battery and smelter) produced higher risks for cancer of the stomach (RR 1.50, 95%CI 1.23-1.83), lung (RR 1.42, 95%CI 1.05-1.92) and kidney (RR 1.26 95%CI 0.70-2.28). [Only one study reported data for bladder cancer and no meta-analysis was performed]. Because of lack of data, potential confounders as, for example, other occupational exposures, smoking and dietary habits were not explicitly controlled for. Notwithstanding this serious limitation, the increased RR’s supporting the hypothesis of an association between stomach and lung cancer and heavy exposure to lead are unlikely to be entirely due to confounding. For bladder cancer, only 4 of the 14 reviewed studies reported relevant results; hence, due to possibly unpublished negative findings, the meta-analysis may have overestimated the risk. By the same token, results for kidney cancer should be considered limited and only suggestive of a true effect.

Some further evidence on the possible carcinogenicity of lead was provided by recent studies in Northern countries and Italy. One study reported on 20,700 Finnish workers biologically monitored for blood lead levels during 1973-83 and grouped by the highest personal blood lead concentration (0.0-0.9 µmol/l; 1.0-1.9 µmol/l; 2.0-7.8 µmol/l). The follow-up of cancer incidence showed increases of overall cancer, digestive cancer, lung cancer (in both men and women), bladder cancer and, suggestively, of cancer of the nervous system (in both men and women) in comparison with the general population. The increases were particularly evident in the intermediate category: all cancers SIR 1.2, 95%CI 1.0-1.4; digestive cancer SIR 1.3 95%CI 0.9-1.8; lung (men) SIR 1.4, 95%CI 1.0-1.9; lung (women) SIR 4.4, 95%CI 0.5-16; bladder SIR 2.0 95%CI 1.0-3.6; nervous system (men) SIR 1.3, 95%CI 0.5-2.7; nervous system (women) SIR 3.8, 95%CI 0.5-14. Few cases occurred in the highest blood-lead group. An internal comparison with workers with blood lead concentration < 1.0 µmol/l confirmed the increase of all malignancies (RR 1.4, 95%CI 1.1-1.8) and lung cancer (RR 1.8, 95%CI 1.1-3.1). The increase was evident in both men and women. In a nested case-control study, the effect of several possible confounders (including smoking) was taken into account. The elevated lung cancer risk appeared to be magnified by concomitant exposure to lead and leaded engine exhaust (Anttila et al., 1995). In a later study, the risk of nervous system cancer was investigated in this same study-base using a within-cohort comparison. In the blood lead exposure groups 1.0-1.9 µmol/l; 2.0-7.8 µmol/l, the results were RR1.6, 95%CI 0.7-3.8, and RR 1.8, 95%CI 0.6-5.8, respectively. The case-referent study included 26 nervous system cancers (16 gliomas). Exposure to > 1.4 µmol/l lead produced an OR 2.2, 95%CI 0.7-6.6 in comparison with exposure to < 0.7 µmol/l. For glioma, the risk associated with the high exposure group was OR 11.0, 95%CI 1.0-626. Adjustment for known confounders changed the results numerically without altering the picture (Anttila et al., 1995).
Wong and Harris (2000) studied the cancer mortality of a cohort of 4518 workers at lead battery plants and 2300 at lead smelters and compared this with the cancer mortality rate of the male U.S. population. In addition, a nested case-control study of stomach cancer was performed. A significant mortality increase from stomach cancer (SMR=147.4, 95%CI: 112.5-189.8) was found. Based on the results of the nested case-control study, this was not regarded as being related to lead exposure. No increased mortality was found for cancers of the kidneys, bladder, CNS, lymphatic and haematopoietic system. A small, but statistically significant increase of lung cancer mortality was ascribed, in absence of an exposure-response, to confoundings from tobacco smoking.

The carcinogenicity of lead was the matter of a recent IARC conference held in Gargnano, Italy (see Landrigan et al., 2000). The results of this conference have been considered by SCOEL. Specifically, an update of the previous epidemiological metaanalysis of Fu and Boffetta (1995) corroborated the earlier conclusions (Steenland and Boffetta, 2000). It was summarized that most of the epidemiologic studies on the carcinogenicity of lead did not present adequate data on dose-response. The current evidence was considered as "somewhat suggestive of an association between lead, lung and stomach cancers, and weaker in the cases of kidney cancer and brain cancer (Landrigan et al., 2000). In one Swedish cohort consisting of 3979 primary lead smelter workers employed for at least 1 year between 1928 and 1979, followed between 1955 and 1987, there was an increased incidence of lung cancer (SIR 2.9, 95% CI 2.1-4.0) in comparison with the county population. In the sub-cohort study solely exposed to lead, the lung cancer SIR was 3.19 (95%CI 1.7-5.2) and was higher for those exposed before 1950 (SIR 3.7, 95%CI 1.8-6.6). Blood-lead analyses were available since 1950, and the lung cancer incidence was estimated in relation to cumulative lead in blood exposure categories. The results were: blood lead 0-2 µmol/l, no cases observed, 1.4 expected; 2-10 µmol/l, SIR 4.5, 95%CI 1.8-9.3; > 10 µmol/l, SIR 5.1, 95%CI 2.0-10.5. No excess of malignancies other than lung was noted in the lead only exposed sub-cohort (Lundström et al., 1997). Another cohort from Sweden, comprising 664 lead-battery workers, was studied for mortality and cancer incidence. Mortality from all cancers (RR 1.65, 95% CI 1.09-2.44) and ischaemic heart disease (RR 1.72, 95%CI 1.20-2.42) was significantly increased. Blood-lead measurements were available, but no dose-response pattern was visible. Compared with the county population, the tumour incidence was slightly elevated mainly due to a nearly twofold increase of gastrointestinal cancers (SIR 1.84, 95%CI 0.92-3.29), affecting mainly those employed before 1970 (SIR 2.14, 95%CI 0.98-4.07) and particularly evident after 15-year latency (SIR 2.44, 95%CI 1.22-4.37). The GI malignancies risk for the quartile of workers with the highest cumulative lead dose was: SIR 2.34, 95%CI 1.07-4.45. No excesses of lung, brain or urinary cancers were found (Gerhardsson et al., 1995). In an Italian cohort of 1388 workers in a lead-smelting plant, the risks of bladder (RR 1.45, 95%CI 0.74-2.53), kidney (RR 1.75, 95%CI 0.48-4.49) and brain cancer (RR 2.17, 95%CI 0.57-5.57) were non-significantly increased. Kidney cancer mortality increased with duration of employment, and was significant among smelter workers employed for 21 years or more (2 cases, RR 10.9, 95%CI 1.0-121). Concomitant exposure to cadmium could not be ruled out. No increases were seen for stomach and lung cancer. Deaths due to respiratory disease were significantly in excess; exposure to silica might have been relevant in some work areas of the smelting plant (Cocco et al., 1997).
Conclusions: IARC has concluded that the epidemiological evidence is “inadequate” whilst the data from animal experiments provide sufficient evidence of carcinogenicity (IARC, 1987). Taking into account also the evidence of chromosome damage in exposed workers, IARC has classified lead as possibly carcinogenic for humans (group 2B). Based on the results of a recent IARC conference held in Gargnano, Italy, it has been stated that lead should be regarded as a proven animal carcinogen, and that new data on the cancer risk of workers exposed to lead would probably justify a re-evaluation by ARC in the near future (Landrigan et al., 2000).

The studies on mutagenic and carcinogenic effects of lead in humans have been criticised mainly because (a) the differences between lead compounds were not taken into consideration, (b) exposure has not been adequately measured, (c) the predominance of mortality studies which are more suitable for generating hypotheses than for validating them, (d) the failure to adequately account for confounding factors (smoking, alcohol), and other substances (As, Cr, Cd), (e) the insufficient sample size for valid detection of a relatively small excess risk (Copper et al., 1985; Fanning, 1988; Gerhardsson et al., 1986; Apostoli et al., 1989). There is also a discrepancy between the suggested sites of tumour formation in humans as opposed to experimental animals (kidneys).

Based on experimental data it seems plausible that the carcinogenicity of lead is based on indirect, rather than on direct genotoxic mechanisms (Silbergeld et al., 2000). This could imply the existence of a practical threshold for the carcinogenic effects, and would argue in favour of the possibility of setting an health-based OEL for lead. However, further research into the mechanisms of lead genotoxicity and carcinogenicity should be encouraged in order to strengthen this avenue of argumentation.

Effects of Haem Synthesis

In the past 10 years, growing attention has been paid to subclinical effects and indeed to early or subtle health effects, the hypothesis being that these form a physiopathogenic continuum with the clinical or generally overt effects (EPA, 1986; Goyer, 1990).

Lead inhibits enzymes of haem synthesis in a dose-dependent manner (both as regards prevalence and severity) and there are a number of related parameters for which it is possible to tentatively identify PbB levels at which changes cannot be detected; ZPP: 20 µg/dl; coproporphyrin: 40 µg/dl; urinary and blood δ-aminolevulinic acid levels: 30 to 35 µg/dl; δ-aminolevulinic acid dehydrase: 10 µg/dl; inhibition of iron chelation: 20-25 µg/dl. However, the clinical significance of these biochemical changes is uncertain. Although the data-base is weak, there appears to be a risk of developing lead-induced anaemia (haemoglobin concentration < 14 g/dl) at PbBs in excess of about 50 µg/dl (IPCS, 1995; ATSDR, 1992; Silbergeld, 1990). Masci et al. (1998) have conducted a longitudinal study on workers performing tin/lead alloy welding. Blood lead levels of these workers gradually declined with time to lower values (6-34 µg/dl, accompanied by similar decreases in zinc protoporphyrin concentrations (2-47 µg/dl); there by it appeared that effects on haem synthesis (which might be regarded as non-adverse) occur even at very low levels of Pb exposure (see Figure 1).
Conclusion: Some subclinical changes in parameters of haem synthesis may occur even below 40 µg Pb / dl blood, but these are not regarded as being "adverse".

Effects on Blood Pressure

The effect of lead on blood pressure has been widely investigated in recent years (Prikle et al, 1985; Sharp et al., 1987; Kopp et al., 1988; Micciolo et al., 1994). Experiments have demonstrated that lead effects the soft muscles of the vessels by interfering with the Na-K system, cAMP, Ca and the renin angiotensin system. The biological plausibility of a causal relationship between an elevated blood pressure and lead exposure has been mainly investigated in animal experiments and in vitro tests. The most likely mechanisms include interference with the balance between the renin-aldosterone axis and the renal kallikrein system, direct action at the level of the vascular smooth muscle cell and the potentiation of sympathetic stimulation. The available literature suggests that there is a positive association between systolic blood pressure and the blood lead concentration. By contrast, the correlation with diastolic blood pressure was much less consistent across the various studies and in the overall analysis attained statistical significance only because of one strongly positive survey (Gartside, 1988). Whether the association between systolic pressure and blood lead is causal in terms of morbidity or mortality is not proven.

Assuming a causal and reversible relationship between blood pressure and blood lead, the potential health risks of lead exposure were examined in white men via far-reaching extrapolations from the multiple logistic regression models obtained in the Pooling Project and in the Framingham Study. These calculations suggested that a 37% decline in blood lead concentration as observed in the US from 1976 to 1980, would result over 10 years in a 5% fall in the incidence of fatal and non-fatal myocardial infarction, in a 7% decrease in the rate of fatal and non-fatal strokes and in a 5 to 6% decrease in total mortality. None of the epidemiological studies have demonstrated the existence of a threshold dose in a wide range of "low" doses (7-35 µg/dl) (Prikle et al, 1985; Sharp et al., 1987; Kopp et al., 1988; Micciolo et al., 1994).

Conclusion: There is the need of further research on the effects of Pb on blood pressure. Whether low levels of lead (up to 40 µg/dl blood) might cause effects which should be considered as being "adverse" is not clear at present.

Effects on the Peripheral Nervous System

Studies of peripheral nerve toxicity, based upon measurement of nerve conduction velocity (NCV) provide further evidence of a causal relationship between a reduction in NCV and PbB greater than 70 µg/dl, with possible effects at PbB as low as 30 µg/dl (Seppäläinen et al., 1983). This is contradictory to earlier studies by Spivey et al. (1980) who did not find NCV changes in lead smelters with blood levels of 60 to 80 µg/dl. Moreover, the data of Seppäläinen et al., (1983) were not confirmed thereafter as more recent studies also demonstrated no effect on NCV at levels below 70 µg/dl PbB
The peripheral nerve toxicity of lead has been connected with an effect of interaction of Pb/Ca, which has been observed at the level of the neuromuscular junctions, with an antagonism between the two cations in regulating the synaptic transmitter.

**Conclusion:** There is no consistent proof of effects of Pb on the peripheral nervous system at levels up to 40 µg/dl blood.

**Neurobehavioural Studies**

Several studies concerned with the neurobehavioural effects of occupational exposure to lead have reported changes in performance in neuropsychological tests at PbBs of around 40 µg/dl and above (Spurgeon, 1994). Effects on performance in neuropsychological tests were found in all studies at blood lead levels well below 70 µg/dl.

Table 1 gives a compilation of studies which were considered relevant and adequate for OEL setting. In general, mean actual PbB levels of 40-50 µg/dl are a range in which subjective symptoms and objective performance impairments are found. A recent paper of Lindgren et al. (1996) reports on the lowest exposures associated with statistically significant effects. A group with mean actual PbB values of 26.9 µg/dl (± 19.5 S.D.) and a mean long-term PbB average of 40 µg/dl showed performance deficiencies. However, no dose-response relationship was seen in this study, and significance was only found following unusual statistical analysis. On the basis of a very recent meta-analysis by Meyer-Baron and Seeber (2000) it appears that neurobehavioural studies indicating effects in the region of 40 µg Pb / dl blood are more convincing. Meyer-Baron and Seeber (2000) have considered 22 human neurobehavioural studies covering lead exposure conditions of <70 µg Pb / dl blood. As a consequence of the use of different test procedures in these studies and insufficiently documented test results only 13 tests out of 12 studies could be included in their meta-analysis. For the tests "Block Design", "Logical Memory" and "Santa Ana" performance deficits were found which may be interpreted as "small"effects in accordance with a convention for evaluating effect sizes. For the example of "Block Design" it was argued that these effects are nevertheless serious. The extent of exposure-related decrease in performance was comparable with those changes in performance which can be expected during aging of up to 20 years.

**Conclusion:** In total, consistent neurobehavioural effects which are to be considered as "adverse" appear in a multiplicity of studies at lead blood levels of 40 µg/dl and above. The dose-dependency of impairments in performance in neurobehavioural tests, in relation to PbB levels, may also be drawn from the studies of Mantere et al., (1982) and Stollery et al., (1989, 1991). In general, decreases in global performance are reported at PbB levels >40 µg/dl (Schwartz and Landrigan, 1988; Landrigan, 1990). This is supported by a recent meta-analysis of Meyer-Baron and Seeber (2000). It should be mentioned that no publication addresses the open question of gender specificity in an
adequate manner. The behavioural studies have been almost exclusively conducted in males; where (limited numbers of) females are also involved, generally no valid gender-specific data are provided.

Nephrotoxicity and Gastrointestinal Toxicity

High exposure to lead can induce kidney toxicity involving acute tubular damage and chronic interstitial fibrosis. Kidney toxicity has not been adequately investigated in modern occupationally-exposed groups, but the limited studies available give no clear evidence of lead-induced renal pathological or functional changes at PbBs below 70 µg/dl (Buchet et al., 1980; Pollock and Ibels, 1988). Colic is a recognised symptom of lead-poisoning, associated with PbBs in excess of 100 µg/dl. A number of studies suggest that there is an increased risk of gastrointestinal problems in lead-exposed workers with a PbB in excess of 60 µg/dl (Baker et al., 1979; Lilis et al., 1977), but firm conclusions cannot be drawn because of shortcomings in the study designs.

Conclusion: There is no evidence of nephrotoxic and/or gastrointestinal toxicity at Pb blood levels of 40 µg/dl and below.

Reproductive Toxicity

A few epidemiological studies have been performed on the association between paternal exposure to lead and adverse reproductive outcome. The results suggest an increased risk of spontaneous abortion, perinatal death and low birth weight following paternal occupational lead exposure (Lindbohm et al., 1991; Kristensen et al., 1993; Anttila and Sallmén, 1995; Min et al., 1996). In a Finnish study, a significant increase was observed in the risk of spontaneous abortion among the wives of men whose PbB was 30 µg/dl or higher during spermatogenesis (Lindbohm et al., 1991). Reduced fertility has also been reported for men with a long duration of lead exposure (Lin et al., 1996). There is limited evidence of an association between reduced semen quality (reduced sperm count and motility and increased morphologically abnormal sperm) and PbB in excess of about 40 µg/dl (Alexander et al., 1996; Assenato et al., 1986; Lancranjan et al., 1975). From a recent review on male reproductive toxicity of lead (Apostoli et al., 1998), it seems evident that only Pb levels above 40 µg/dl in blood are associated with a decrease in sperm count, volume and morphological alterations.

There are no data on female fertility relating to modern occupational exposure levels. Lead is transferred across the placenta during the 12th to 14th weeks of pregnancy.

At birth the blood lead concentration in the umbilical cord of the child is close to the blood lead level of the mother (80-90%). Consequently, the child of a pregnant woman employed in a lead trade may have at birth a blood lead level exceeding considerably that of the unexposed population. Blood lead levels have also been observed to increase during pregnancy despite unchanged or decreasing environmental lead levels. The mobilisation of lead from bone during pregnancy probably explains the increase
Studies of the influence of pre- and post-natal low-level environmental lead exposure on *in utero* and childhood development show no evidence of an association between lead exposure and spontaneous abortion or birth defects. Several studies reported a correlation between reduced length of gestation (McMichael *et al.*, 1986; Moore *et al.*, 1982) and reduced birth weight in full term deliveries (Bellinger *et al.*, 1984; Bornschein *et al.*, 1987) with maternal PbBs as low as about 20 µg/dl, but other studies do not support these observations.

Impaired cognitive development in children exposed to lead during gestation has also been reported at blood lead levels of 15 µg/dl or more in three prospective studies (Bellinger *et al.*, 1987; Dietrich *et al.*, 1993; Ernhard *et al.* 1989) but not in two others (Cooney *et al.*, 1989; Baghurst *et al.* 1992). Effects of maternal lead exposure cannot be distinguished from early childhood exposure due to other sources but toxicokinetic considerations indicate that effects on neurological and psychomotor development is a possible but uncharacterisable risk from maternal exposure to the fetus or breast-fed infant. It also must be pointed out that in the studies on mental child development umbilical blood lead levels, but not maternal levels throughout pregnancy have been determined.

**Conclusions:** Signs of male reproductive toxicity appear consistently at Pb blood levels above 40 µg/dl. These effects should be considered as adverse. The effect of reproductive toxicity in females, which is of highest potential impact and which is to be regarded as adverse, is impairment of the cognitive development in newborns and infants. A definite threshold for this effect cannot be derived from the present literature data. However, there are uncertainties and inconsistencies in the present database.

Because of the greater susceptibility of females (particularly with regard to these reproductive, but also to haematological effects, it has been suggested that lower limits should be maintained for female workers (Zielhuis, 1985).

**Recommendation:**

The leading toxic effect of lead in males and females is impairment of performance in neurobehavioural tests. Most authors agree that a long-term PbB level of 40 µg/dl probably represents a LOAEL in this respect; since subtle effects have been experienced by some individuals at PbB levels of 40 µg/dl. One particular study (Lindgren *et al.*, 1996) reports on neurobehavioural effects at lower concentrations.

Other endpoints of lead toxicity, namely PNS and renal toxicity, are relevant for exposure levels which are consistently higher (*Fig. 1*). The observed experimental carcinogenicity of Pb salts is, in the first instance, directed towards the kidneys as the target tissue. Most probably, these effects are to a great extent based on the renal toxicity of high doses of Pb. There is an ongoing discussion on the human carcinogenicity of lead and lead compounds. Based on experimental findings it seems plausible that lead has no direct genotoxic effect which argues in favour of existence of practical thresholds of carcinogenicity. Hence an OEL based on avoiding functional CNS alterations is expected also to protect against PNS and renal toxicity, including
possible renal cancer development. Similar conclusions may probably be drawn with respect to other systemic toxicities, e.g. on haem biosynthesis and on blood pressure, although there is a discrepancy in opinions and more research is needed in this direction.

There is considerable uncertainty concerning impairment of reproductive function by lead. For males, there are valid indications that only PbB levels above 40 µg/dl are connected with impairment of fertility. In females, however, it is relevant that cognitive deficits of the offspring are dose-dependently associated with lead exposure. The question of reversibility of such deficits is not yet satisfactorily resolved. On the basis of the present data no definite NOAEL can be deduced, which calls for a minimization of exposure.

Another aspect to be observed is the existing background levels which result from environmental sources, even without overt occupational exposures. In most EU countries, the background PbB levels have decreased during the last 20-30 years from ~20 µg/dl to ~5 µg/dl. However, there are areas where higher levels are still being found, mainly due to the former use of lead materials in water installations (e.g., in some areas of Eastern Germany).

On this basis, the following recommendation is given:

1. Biological limit values

   PbB: 30 µg/100 ml

   It should be kept in mind that the recommended BLV is not seen as being entirely protective of the offspring of working women. No threshold for potential central nervous system effects in new born and infants can be identified at present. The exposure of fertile women to lead should therefore be minimised.

2. Occupational Exposure Limits (OEL)

   Only part of the occupational exposure occurs by inhalation and a considerable portion is incorporated after oral ingestion. Lead ingestion varies as a function of personal hygiene of the individual and the overall cleanliness of the work environment. In consequence, the setting of an OEL for airborne lead is more difficult than for other compounds.

   Based on the field studies on lead battery workers by Lai et al. (1997) and others (see Kentner and Fischer 1993) and using the preferred values approach of SCOEL, an OEL for airborne exposure of 100 µg/m³ is recommended as consistent with the above biological limit value.
Key Bibliography:


Meyer-Baron, M., Seeber, A. (2000) A meta-analysis for neurobehavioural results due to occupational exposure with blood lead concentrations < 70 µg/100 ml. Arch. Toxicol. 73, in press.


Table 1. Epidemiological studies of occupational exposure to lead which meet the criteria for a discussion of limit values

Key – CG: control group(s); EG: exposed group(s); TWA: "time-weighted average"; IBL: cumulative blood lead; AM: arithmetic mean(s)

<table>
<thead>
<tr>
<th>Exposed group/control group</th>
<th>Exposure variables</th>
<th>Tests/variables</th>
<th>Significant group differences</th>
<th>Significant dose-effect relationships</th>
<th>Confounder control</th>
<th>Assessment of examination</th>
</tr>
</thead>
</table>
| Lindgren et al. 1996        | Exposed group: 467 male employees/lead smelting | Present PbB: 28/8 (AM/SD) | 9/14 | Not examined | Re IBL: | No significant differences as regards:
|                             |                    | Range ? | | | Digital symbol test | Language |
|                             |                    | TWA PbB: 40/4-66 (AM/range) | | | Logical memory (short-term) | Minor neurological disorders |
|                             |                    | IBL (cumulative blood lead over entire duration of employment): 765/0.6-1626 µg-dl (AM/range) | | | Trail making (two variables) | |
|                             | Low: 269/195 (AM/SD) | | | | Purdue pegboard (dominant hand) | |
|                             | Medium: 821/122 (AM/SD) | | | | | |
|                             | High: 1228/145 (AM/SD) | | | | | |

Exclusion criteria
- Serious neurological disorders
- Pre-existing short-term psychiatric disorders

Account taken of significant differences as regards:
- Age
- Education level
- Depression
- Alcohol consumption

Examination blind/exposure
- Examinations at start of shift

Satisfactory inclusion of all relevant confounders in the analysis
<table>
<thead>
<tr>
<th>Exposed group/control group</th>
<th>Exposure variables</th>
<th>Tests/variables</th>
<th>Significant group differences</th>
<th>Significant dose-effect relationships</th>
<th>Confounder control</th>
<th>Assessment of examination</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposed group: 43 workers/ lead smelting</td>
<td>• Present PbB: EG: 43/12/9-68 (AM/SD/range)</td>
<td>7/14</td>
<td>Exposed Group v. Control group</td>
<td>Re present PbB&gt;PbB max &amp; TWA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control group: 47 workers/glass factory</td>
<td>CG: 15/6 (AM/SD) &lt;10 4% 10-25 44% 25-39 20% 40-61 26% 61-81 6%</td>
<td></td>
<td>• Symptom indications in year before examination (Concentration; annoyed or agitated without reason; unusual fatigue; aching joints)</td>
<td>Re present PbB: • POMS (tension/fear; hostility; fatigue; depression)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Maximum PbB (1986-1993): EG: 60/20 (AM/SD)</td>
<td></td>
<td></td>
<td>Re maximum PbB: • POMS (hostility; depression)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CG: 15/6 (AM/SD)</td>
<td></td>
<td></td>
<td>TWA-PbB: • POMS (hostility; depression)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• TWA PbB: EG: 48/12 (AM/SD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CG: 15/6 (AM/SD)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Comparability of groups regarding: • Activity • Geographical origin</td>
<td>Account taken of influences of: • Age • Education • Alcohol consumption • Earlier exposure to solvents • State of health</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Examinations not blind</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Satisfactory account taken of confounders</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>• Owing to extensive redundancies of long-term exposed workers shortly before the examination, the representativeness of the sample is questionable (&quot;healthy worker effect&quot;?)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exposed group/control group</td>
<td>Exposure variables</td>
<td>Tests/variables</td>
<td>Significant group differences</td>
<td>Significant dose-effect relationships</td>
<td>Confounder control</td>
<td>Assessment of examination</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>--------------------</td>
<td>----------------</td>
<td>------------------------------</td>
<td>----------------------------------</td>
<td>------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td><strong>Stollery et al. 1989</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Exposed group: 86 workers/battery factory/printing industry | • Present PbB:  
Low: <20  
Medium: 21-40  
High: 41/-80  
Range: 5-72 |  • ALA:  
Gr 1: 2.5  
Gr 2: 4.0  
Gr 3: 5.7  
Range: 0.5-22 mg/l |  • Present PbB:  
Low: <20  
Medium: 21-40  
High: 41/-80  
Range: 5-72 |  |  |  |
|                          |  |  | High v. Medium + Low  |  • Semantic classification and recollection (identification of distracters)  
• Serial reaction (number of tests; decision time; motion time)  
• Serial reaction (fewer tests; decision time; motion time)  
Re present PbB:  
• Semantic classification and recollection (three variables)  
• Serial reaction (fewer tests; decision time; motion time)  
• Semantic classification and recollection (three variables)  
• Serial reaction (fewer tests; decision time; motion time)  
Re present PbB:  
• Semantic classification and recollection (three variables)  
• Serial reaction (fewer tests; decision time; motion time)  
• Semantic classification and recollection (three variables)  
• Serial reaction (fewer tests; decision time; motion time)  
Re present PbB:  
• Semantic classification and recollection (three variables)  
• Serial reaction (fewer tests; decision time; motion time)  
• Semantic classification and recollection (three variables)  
• Serial reaction (fewer tests; decision time; motion time)  
Re present PbB:  
• Semantic classification and recollection (three variables)  
• Serial reaction (fewer tests; decision time; motion time)  
• Semantic classification and recollection (three variables)  
• Serial reaction (fewer tests; decision time; motion time)  
Re present PbB:  
• Semantic classification and recollection (three variables)  
• Serial reaction (fewer tests; decision time; motion time)  
• Semantic classification and recollection (three variables)  
• Serial reaction (fewer tests; decision time; motion time)  
Re present PbB:  
• Semantic classification and recollection (three variables)  
• Serial reaction (fewer tests; decision time; motion time)  
• Semantic classification and recollection (three variables)  
• Serial reaction (fewer tests; decision time; motion time)  
Re present PbB:  
• Semantic classification and recollection (three variables)  
• Serial reaction (fewer tests; decision time; motion time)  
• Semantic classification and recollection (three variables)  
• Serial reaction (fewer tests; decision time; motion time)  
Re present PbB:  
• Semantic classification and recollection (three variables)  
• Serial reaction (fewer tests; decision time; motion time)  
• Semantic classification and recollection (three variables)  
• Serial reaction (fewer tests; decision time; motion time)  
Re present PbB:  
• Semantic classification and recollection (three variables)  
• Serial reaction (fewer tests; decision time; motion time)  
|  |  |  |  | Account taken of influences of:  
• Exposure duration  
• Age  
• Age/school-leaving qualifications  
• Sleep  
• Alcohol consumption  
• Activity  
• Stress/arousal  
Comparability of groups as regards:  
• Ethnic origin  
• Regional origin  
Computer testing  |  |  |

Unclear whether account taken of pre-existing diseases  
Largely satisfactory account taken of confounders
<table>
<thead>
<tr>
<th>Exposed group/control group</th>
<th>Exposure variables</th>
<th>Tests/variables</th>
<th>Significant group differences</th>
<th>Significant dose-effect relationships</th>
<th>Confounder control</th>
<th>Assessment of examination</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yokoyama et al. 1988</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exposed group: 19 workers/foundry</td>
<td>Present PbB:</td>
<td>Time 1:</td>
<td>Exposed workers at time 1:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control group: 12 workers/foundry (same establishment)</td>
<td>EG: 30-64 (range)</td>
<td>High v. Low:</td>
<td>Re present PbB:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>After 2 years 17/10</td>
<td>CG: 8-20 (range)</td>
<td>• Pictures to be completed</td>
<td>• Pictures to be completed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>High: 40-64</td>
<td>High v. Control:</td>
<td>Mpb:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Low: 30-39</td>
<td>• Pictures to be completed</td>
<td>• Pictures to be completed</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Control: 8-20</td>
<td>Time 2:</td>
<td>Exposed workers at time 2:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Present PbB after 2 years</td>
<td>None found</td>
<td>Not reported</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>High: 26-59**</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Low: 24-39</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Control: 8-14</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Lead in urine (Mpb)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Comparability of groups as regards:
- Age
- Education
- Alcohol consumption
No exposure to other neurotoxins
No significant pre-existing diseases
No alcohol or drug consumption on test day

- CG younger
- Exposed group drinks more
- As performance effect declines with lead level, both points seem to be of subsidiary importance
<table>
<thead>
<tr>
<th>Exposed group/control group</th>
<th>Exposure variables</th>
<th>Tests/variables</th>
<th>Significant group differences</th>
<th>Significant dose-effect relationships</th>
<th>Confounder control</th>
<th>Assessment of examination</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposed group: 288 workers/3 battery factories</td>
<td>• Present PbB: 40/13 (AM/SD) Range ??</td>
<td>17/18</td>
<td>None</td>
<td>Re present PbB: • Psychosocial variable (conflicts) Re ZPP: • Psychosocial variable (conflicts) Re TWA-PbB: • Psychosocial variables (conflicts, two variables) • Annoyance • Number of accidents</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control group: 181 HGV construction</td>
<td>• TWA PbB: 49/12 (AM/SD) • PbB &gt; 60 0.23/0.22 (AM/SD) • ZPP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Parkinson et al. 1986</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Comparability of groups as regards: • Ethnic origin • Psychiatric history • Drug/alcohol abuse Account taken of influences of: • Age • School education • Income CG had no known exposure to neurotoxins Exclusion criteria: • Significant neurological or other disorders</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exposed group: 288 workers/3 battery factories</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control group: 181 HGV construction</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exposed group/control group</td>
<td>Exposure variables</td>
<td>Tests/variables</td>
<td>Significant group differences</td>
<td>Significant dose-effect relationships</td>
<td>Confounder control</td>
<td>Assessment of examination</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>--------------------</td>
<td>----------------</td>
<td>-------------------------------</td>
<td>-----------------------------------</td>
<td>-------------------</td>
<td>--------------------------</td>
</tr>
<tr>
<td>Hogstedt et al. 1983</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Exposed group: 49 workers subjected to occupational medical checks/lead smelting/battery factory</td>
<td>• Present PbB:</td>
<td>7/7</td>
<td>Low v. Control:</td>
<td>Significance unclear</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>EG: 42 (AM)</td>
<td></td>
<td>• Memory factor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CG: 15 (AM)</td>
<td></td>
<td>• Learning factor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TWA PbB:</td>
<td></td>
<td>High v. Control:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>EG: 48 (AM)</td>
<td></td>
<td>• Memory factor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Highest individual value 65</td>
<td></td>
<td>• Simple reaction time</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>14 persons had &gt; 69 once</td>
<td></td>
<td>High + Low v. Control:</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Range 27-69</td>
<td></td>
<td>• Memory factor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>High: &gt; 53</td>
<td></td>
<td>• Learning factor</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Low: 27-52</td>
<td></td>
<td>• Simple reaction time</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Control: &lt;21</td>
<td></td>
<td>• Neuropsychiatric symptoms</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ZPP</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Control group: 27 industrial workers subjected to occupational medical checks/wire industry/turning shop/munitions factory:</td>
<td>• Present PbB:</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>EG: 42 (AM)</td>
<td>EG: 42 (AM)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>CG: 15 (AM)</td>
<td>CG: 15 (AM)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TWA PbB:</td>
<td>TWA PbB:</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>EG: 48 (AM)</td>
<td>EG: 48 (AM)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Highest individual value 65</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>14 persons had &gt; 69 once</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Range 27-69</td>
<td>Range 27-69</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>High: &gt; 53</td>
<td>High: &gt; 53</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Low: 27-52</td>
<td>Low: 27-52</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Control: &lt;21</td>
<td>Control: &lt;21</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>ZPP</td>
<td>ZPP</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- Lack of differences in verbal tests testify to comparable premorbid intelligence
- Satisfactory account taken of confounders
- Differences in proportion of shift workers in exposed group and control group may lead to underestimating of effects, as performance of shift workers was generally inferior
### PbB levels-related effects of lead in exposed workers

<table>
<thead>
<tr>
<th>Lowest observed effect level (PbB)</th>
<th>Heme synthesis and hematological effects</th>
<th>Neurological effects</th>
<th>Effects the Kidney</th>
<th>Reproductive function effects</th>
<th>Cardiovascular effects</th>
</tr>
</thead>
<tbody>
<tr>
<td>µg/dl</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>100-120</td>
<td>Encephalopathic signs and symptoms</td>
<td>Chronic neophropathy</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>80</td>
<td>Frank anemia</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>60</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>50</td>
<td>Reduced hemoglobin production</td>
<td></td>
<td></td>
<td></td>
<td>Female reproductive effects</td>
</tr>
<tr>
<td>40</td>
<td>Increased urinary ALA and elevated coproporphyrins</td>
<td>Neurobehavioural impairment</td>
<td>Early signs of kidney malfunctions</td>
<td>Altered testicular function</td>
<td></td>
</tr>
<tr>
<td>30</td>
<td></td>
<td></td>
<td></td>
<td>Elevated blood pressure (White males Aged 40 –55)</td>
<td></td>
</tr>
<tr>
<td>25-30</td>
<td>Erythrocyte protoporphyrin (EP) elevation in males</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>15-20</td>
<td>Erythrocyte protoporphyrin (EP) elevation in females</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt; 10</td>
<td>ALA-D inhibition</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>